News - Bristol-Myers Squibb

Filter

Current filters:

Bristol-Myers Squibb

Popular Filters

1 to 25 of 234 results

Bristol-Myers and Ono Pharma enter Asia oncology accord

24-07-2014

US pharma major Bristol-Myers Squibb and Japan’s Ono Pharmaceutical have signed a strategic collaboration…

Asia-PacificBristol-Myers SquibbJapanLicensinglirilumabOncologyOno PharmaceuticalOpdivoPharmaceuticalurelumabYervoy

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending…

Astellas PharmaBristol-Myers SquibbOncologyPharmaceuticalRegulationUKXtandiYervoy

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

17-07-2014

Ahead of the International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool has announced…

Anti-viralsatazanavirBristol-Myers SquibbdolutegravirGenericsGilead SciencesMedicines Patent PoolRoche

Bristol-Myers to file Opdivo BLA earlier than expected

Bristol-Myers to file Opdivo BLA earlier than expected

10-07-2014

Following discussions with the US Food and Drug Administration, Bristol-Myers Squibb is planning a third…

Bristol-Myers SquibbnivolumabOncologyOpdivoPharmaceuticalRegulationUSA

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

07-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic…

Anti-viralsBristol-Myers SquibbDaklinzaDaklinza+SunvepraJapanPharmaceuticalRegulationSunvepra

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP

27-06-2014

At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbasriaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Bristol-Myers Ph III nivolumab trial stopped early on good results

Bristol-Myers Ph III nivolumab trial stopped early on good results

25-06-2014

Shares of US pharma major Bristol-Myers Squibb rose 2.6% to $49.55 in post-market trading on June 25,…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearch

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment

20-06-2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

Arrival of new hepatitis C therapies will increase the drug-treated population in China

Arrival of new hepatitis C therapies will increase the drug-treated population in China

19-06-2014

China’s market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated…

Anti-viralsasunaprevirBristol-Myers SquibbChinadanoprevirGilead SciencesJanssenMarkets & MarketingOlysioPharmaceuticalRocheSovaldi

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

UK’s NICE says “Yes” to Bristol-Myers’ Yervoy

13-06-2014

People in England with advanced skin cancer should be able to receive ipilimumab as a first treatment…

Bristol-Myers SquibbOncologyPharmaceuticalPricingRegulationUKYervoy

US Court denies appeal in Baraclude patent case

US Court denies appeal in Baraclude patent case

13-06-2014

US pharma major Bristol-Myers Squibb yesterday announced that the US Court of Appeals for the Federal…

Anti-viralsBaracludeBristol-Myers SquibbGenericsLegalPatentsTeva Pharmaceutical IndustriesUSA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

12-06-2014

US drug major Bristol-Myers Squibb has released new data from a Phase IIIb RA trial showing that the…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbOrenciaResearch

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Mylan launches generic Paraplatin Injection in USA

Mylan launches generic Paraplatin Injection in USA

09-06-2014

US generics major Mylan has launched carboplatin injection, 50mg/5ml, in multi-dose vials, which is the…

Bristol-Myers SquibbGenericsMarkets & MarketingMylanOncologyParaplatinRegulationUSA

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

05-06-2014

US pharma major Bristol-Myers Squibb and Syngene International, India’s largest contract research organization,…

BioconBiotechnologyBristol-Myers SquibbIndiaResearchSyngene

ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

ASCO 2014: Strong results for Bristol-Myers Yervoy, and combo with nivolumab

02-06-2014

Among the latest important research results presented at the 2014 prestigious annual meeting of the American…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalResearchYervoy

Bristol-Myers and Incyte sign up to evaluate combo regimen of two immunotherapies

27-05-2014

US pharma major Bristol-Myers Squibb and Incyte Corp have set up a clinical trial collaboration to evaluate…

Bristol-Myers SquibbINCB24360IncyteLicensingnivolumabOncologyPharmaceuticalResearch

Breakthrough designation for B-MS/AbbVie’s MM drug elotuzumab

19-05-2014

The US Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody…

AbbVieBristol-Myers SquibbelotuzumabOncologyPharmaceuticalRegulationUSA

Bristol-Myers’ nivolumab receives US FDA Breakthrough Therapy designation for Hodgkin lymphoma

15-05-2014

The US Food and Drug Administration has granted US drug major Bristol-Myers Squibb’s investigational…

Bristol-Myers SquibbnivolumabOncologyPharmaceuticalRegulationUSA

1 to 25 of 234 results

Back to top